Research Award of the Leibniz Alliance Bioactives and Biotechnology

2018
Leibniz Research Award to honor Prof. Dr. Jay Keasling

The Leibniz Research Award 2018 honors Prof. Dr. Jay Keasling for his groundbreaking achievements in synthetic biology. He is professor of chemical engineering and bioengineering at the University of California, Berkeley. He is also associate laboratory director for biosciences at the Lawrence Berkeley National Laboratory and chief executive officer of the Joint BioEnergy Institute. Prof. Keasling received his bachelor’s degree at the University of Nebraska-Lincoln. He went on to complete his Doctor of Philosophy degree at the University of Michigan in 1991 under the supervision of Bernhard Palsson. Keasling performed post-doctoral research with Arthur Kornberg at Stanford University in 1991-1992.

His research focusses on developing foundational tools for engineering metabolism inside cells and to use those tools to solve important societal problems. A variety of tools have been developed for regulating metabolic pathways inside cells, novel metabolic pathways to produce unnatural molecules, and robust microbial hosts for producing chemicals under a variety of industrial conditions. These tools were used to produce the antimalarial drug artemisinin, a variety of commodity and specialty chemicals, and biofuels.


2017
The LRA Bioactive Compounds and Biotechnology honors the exceptional work of Prof. Dr. Jon Clardy with the Leibniz Research Award

On the Leibniz Conference on Bioactive Compounds 2017, April 10-11, hosted by Deutsche Forschungsanstalt für Lebensmittelchemie (DFA) in Freising, the Alliance proudly handed the Leibniz Research Award to Prof. Dr. Jon Clardy from Harvard Medical School, Boston, USA. With this award they honored his outstanding scientific contributions to the understanding of the biological role of natural compounds – ranging from extraction from uncultured bacteria over structure elucidation to mode-of-action-studies. In a plenary talk during the conference Prof. Clardy gave insight into his research to the highly interested audience.

 


2016
Leibniz Research Award goes to honor
Prof. Dr. Paul A. Wender work

This year for the first time Leibniz Research Alliance Bioactive Compounds and Biotechnology rewarded Leibniz Research Award. The award is granted in recognition of Prof. Dr. Paul A. Wender exceptional research and societal significance in medicine, biology, imaging and materials science at the “Leibniz Wirstofftage 2016 / Leibniz Meeting on Bioactive Compounds 2016” on 25.04.2016. in Jena.

 

PW2

 

Over the past 40 years, Wender and his coworkers have had a unique and major impact on not only how we make molecules but on which molecules to make, merging major advances in synthesis with goals of exceptional research and societal significance in medicine, biology, imaging and materials science. He and his group have made seminal and impactful contributions to a range of sciences driven by synthesis of complex molecules in medicinal chemistry; real-time imaging; drug delivery with designed molecular and oligomeric transporters, nanotubes and nanoparticles; and chemical biology. Wender’s ability to connect innovative design and syntheses of small, medium and large molecules and molecular assemblies with major unmet medical needs is influencing how we think about making molecules and reaction science; leading to new concepts, tools, and companies for drug delivery; and driving new preclinical leads for the treatment of cancer, HIV/AIDS, Alzheimer’s disease, and in small molecule enhanced immunotherapy.

 

PW1


Disclaimer:

Die Preise werden vom Leibniz-Forschungsverbund Wirkstoffe und Biotechnologie ausgegeben, verantwortliche Ansprechperson ist der Koordinator/die Koordinatorin, ersatzweise der/die Sprecher/in des Verbundes. Über die Preisvergabe entscheidet ein vom Verbund bestimmtes Komitee. Bei Nichtannahme oder bei der Preisvergabe widersprechenden Erkenntnissen wird zunächst der nachfolgende Vorschlag berücksichtigt. Das Preisgeld wird an den/die verantwortlichen Seniorwissenschaftler/in der preiswürdigen Erfindung vergeben, ersatzweise an den/die Direktor/in des verantwortlichen Instituts, welche/r über die angemessene und beitragsbezogene Verwendung intern frei entscheidet. Dem/der Koordinator/in ist vom Seniorwissenschaftler/in bis Ende des Preisjahres ein Verwendungsschema mit Überweisungsinformationen zu übermitteln. Die minimale Splittung ist € 100,-. Es besteht kein Rechtsanspruch auf den Erhalt des Preises oder des Preisgeldes. Die Entscheidungen sind nicht anfechtbar, der Rechtsweg ist ausgeschlossen.